{"id":"W2023764867","doi":"10.1016/j.clbc.2012.01.001","title":"Phase II Interventional Study (N0337) of Capecitabine in Combination With Vinorelbine and Trastuzumab for First- or Second-Line Treatment of HER2-Positive Metastatic Breast Cancer: A North Central Cancer Treatment Group Trial","year":2012,"lang":"en","type":"article","venue":"Clinical Breast Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"ca_institutions":"Saskatchewan Cancer Agency","funders":"National Cancer Institute; U.S. Public Health Service; Genentech; National Institutes of Health; Mayo Clinic","keywords":"Vinorelbine; Capecitabine; Medicine; Trastuzumab; Metastatic breast cancer; Internal medicine; Oncology; Breast cancer; Cancer; Phases of clinical research; Chemotherapy; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005156058,0.0004610636,0.001659343,0.0002212535,0.0001012311,0.00001330097,0.0001306001,0.0001129119,0.002031185],"category_scores_gemma":[0.00005392587,0.000302214,0.0003446002,0.0004811492,0.0003922969,0.0001943538,0.00005559981,0.0002137036,7.619102e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002037641,"about_ca_system_score_gemma":0.0011193,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.01018807,"about_ca_topic_score_gemma":0.07804325,"domain_scores_codex":[0.9961931,0.0002708845,0.001567149,0.0006632444,0.0005856442,0.0007199438],"domain_scores_gemma":[0.9974747,0.0006261388,0.0005658251,0.0003502028,0.0004793249,0.000503765],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2185193,0.1092254,0.4784179,0.0004808726,0.002266892,0.00003006215,0.001999774,0.00003703269,0.0000445165,0.00001858735,0.0001228514,0.1888368],"study_design_scores_gemma":[0.2847012,0.1029595,0.6082478,0.0007037108,0.001400618,0.00006328277,0.0004579861,0.0005470576,0.0001811442,0.000006149888,0.0004783273,0.0002533657],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9814221,0.001823794,0.00006984749,0.001725671,0.0004863641,0.00623501,0.008208971,0.00001859479,0.000009709939],"genre_scores_gemma":[0.9927601,0.001419476,0.0001759717,0.0000499686,0.0007800653,0.004114607,0.0002592865,0.00006544553,0.0003751308],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1885834,"threshold_uncertainty_score":0.999943,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1016132208689963,"score_gpt":0.4580827344753126,"score_spread":0.3564695136063163,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}